Monte Rosa Therapeutics Inc

NASDAQ GLUE

Download Data

Monte Rosa Therapeutics Inc Net Current Asset Value 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -49.53%

Monte Rosa Therapeutics Inc Net Current Asset Value 2 year CAGR is -49.53% for the Trailing 12 Months (TTM) ending March 31, 2024. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Monte Rosa Therapeutics Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2023 was 210,731,750.00, a -36.71% change year over year.
  • Monte Rosa Therapeutics Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2022 was 332,972,250.00, a 636.94% change year over year.
  • Monte Rosa Therapeutics Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2021 was -62,013,500.00.
NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO Dr. Markus Warmuth M.D.
IPO Date June 24, 2021
Location United States
Headquarters 645 Summer Street, Boston, MA, United States, 02210
Employees 130
Sector Healthcare
Industry Biotechnology
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email